The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Background: ICE is a commonly used regimen for R/R cHL with complete response (CR) of 60-70%. Panobinostat (P) is a histone deacetylase inhibitor (HDACi) with clinical activity against R/R cHL after transplant with dose limiting toxicity (DLT) of reversible thrombocytopenia. Based on synergistic anti-lymphoma activity of chemotherapy and HDACis in vitro, we conducted a clinical trial combining P and ICE.